

Clinical outcomes in patients with chronic hepatitis C a treatment: a prospective cohort study

Lancet, The

393, 1453-1464

DOI: [10.1016/s0140-6736\(18\)32111-1](https://doi.org/10.1016/s0140-6736(18)32111-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1489-1492.	1.0	13
2	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. <i>Visceral Medicine</i> , 2019, 35, 161-170.	0.5	52
3	The remarkable history of the hepatitis C virus. <i>Microbes and Infection</i> , 2019, 21, 263-270.	1.0	7
4	Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. <i>Clinical Oncology</i> , 2019, 31, 560-569.	0.6	6
5	Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. <i>Hepatology Research</i> , 2019, 49, 1365-1373.	1.8	20
6	Hepatitis C virus elimination: time for disruptive innovation. <i>Journal of the International AIDS Society</i> , 2019, 22, e25360.	1.2	8
7	Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. <i>International Journal of Drug Policy</i> , 2019, 72, 84-90.	1.6	21
8	Editorial: reciprocal interaction between HCV direct-acting anti-virals (DAA) and hepatocellular carcinoma (HCC) – a negative impact of HCC on sustained virologic response not of DAA on HCC. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 227-228.	1.9	2
9	Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e196412.	2.8	56
10	Quality of Life and Work Ability among Healthcare Personnel with Chronic Viral Hepatitis. Evaluation of the Inpatient Rehabilitation Program of the Wartenberg Clinic. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3874.	1.2	2
11	Infectious Complications Following Kidney Transplantation – A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. <i>Medicina (Lithuania)</i> , 2019, 55, 672.	0.8	7
12	Carcinogenesis and Metastasis in Liver: Cell Physiological Basis. <i>Cancers</i> , 2019, 11, 1731.	1.7	26
13	Surgical resection versus radiofrequency ablation very early-stage HCC (≥2cm Single HCC): A propensity score analysis. <i>Liver International</i> , 2019, 39, 2397-2407.	1.9	36
14	Letter: hepatocellular carcinoma negatively affects sustained virological response of direct-acting anti-viral treatment in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 971-973.	1.9	0
15	Hepatitis C. <i>Lancet</i> , The, 2019, 394, 1451-1466.	6.3	285
16	Recent advances in liver transplantation for cancer: The future of transplant oncology. <i>JHEP Reports</i> , 2019, 1, 377-391.	2.6	23
17	Reply to: “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response” <i>Journal of Hepatology</i> , 2019, 71, 447-448.	1.8	0
18	Concerns About Direct-Acting Antiviral Agents for Hepatitis C – Cause for Reassurance. <i>JAMA Network Open</i> , 2019, 2, e194757.	2.8	5

#	ARTICLE	IF	CITATIONS
19	Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS ONE, 2019, 14, e0217751.	1.1	20
20	B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. Journal of Viral Hepatitis, 2019, 26, 1200-1209.	1.0	13
21	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules â€œ A response. Journal of Hepatology, 2019, 71, 446.	1.8	2
22	The remarkable history of the hepatitis C virus. Genes and Immunity, 2019, 20, 436-446.	2.2	30
23	SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells, 2019, 8, 313.	1.8	17
24	Direct-acting antiviral treatment for hepatitis C. Lancet, The, 2019, 393, 1392-1394.	6.3	47
25	Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. Gastroenterology, 2019, 157, 909-916.	0.6	23
26	Value-based Medicine for Patients With Chronic Hepatitis C Infection: Missing the Wood for the Trees. Journal of Clinical Gastroenterology, 2019, 53, 550-551.	1.1	0
27	Quality improvement in hepatitis C screening and treatment in a primary care resident clinic. Journal of Community Hospital Internal Medicine Perspectives, 2019, 9, 471-472.	0.4	0
28	Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication. JHEP Reports, 2019, 1, 480-489.	2.6	10
29	Towards a more comprehensive evaluation of liver fibrosis in patients with chronic hepatitis C. Journal of the Chinese Medical Association, 2019, 82, 807-808.	0.6	0
30	Management of Diabetes Mellitus in Patients with Chronic Liver Diseases. Journal of Diabetes Research, 2019, 2019, 1-9.	1.0	11
31	Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037366.	2.9	7
32	Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?. Journal of the Formosan Medical Association, 2020, 119, 3-11.	0.8	19
33	Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. Modern Rheumatology, 2020, 30, 1009-1015.	0.9	4
34	Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy. Clinical Infectious Diseases, 2020, 70, 2695-2702.	2.9	50
35	Intrahepatic immune changes after hepatitis c virus eradication by directâ€œacting antiviral therapy. Liver International, 2020, 40, 74-82.	1.9	14
36	Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036913.	2.9	19

#	ARTICLE	IF	CITATIONS
37	Comparing interferon-free with interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox. <i>Journal of Viral Hepatitis</i> , 2020, 27, 329-332.	1.0	1
38	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 270-280.	1.0	27
39	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 712-719.	0.8	3
40	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	1.9	24
41	Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036921.	2.9	13
42	Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment. <i>Hepatology Communications</i> , 2020, 4, 314-324.	2.0	11
43	Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 93-101.	0.6	7
44	Hepatitis C virus (HCV) infection and cardiovascular disease: Hepatologists and cardiologists need to talk!. <i>European Journal of Internal Medicine</i> , 2020, 71, 87-88.	1.0	3
45	Epidemiology of Liver Cancer in Africa: Current and Future Trends. <i>Seminars in Liver Disease</i> , 2020, 40, 111-123.	1.8	27
46	Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists: The practitioner experience. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107705.	1.6	40
47	Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?. <i>Aids</i> , 2020, 34, 427-432.	1.0	12
48	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases' Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Hepatology</i> , 2020, 71, 686-721.	3.6	526
49	Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 34-52.	1.9	22
50	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	1.8	49
51	Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa347.	0.4	14
52	All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa308.	0.4	6
53	Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 511-513.	0.7	0
54	Observer-Based Impulsive Controller Design for Treatment of Hepatitis C Disease. <i>Industrial & Engineering Chemistry Research</i> , 2020, 59, 19370-19382.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 671-679.	1.0	41
56	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. <i>Ultraschall in Der Medizin</i> , 2020, , .	0.8	15
57	Elimination of Hepatitis C in Portugal: An Urban Legend?. <i>GE Portuguese Journal of Gastroenterology</i> , 2020, 27, 166-171.	0.3	4
58	High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1593-1600.	0.8	8
59	Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis. <i>Hepatology</i> , 2020, 72, 1897-1899.	3.6	6
60	Treatment of hepatitis C virus infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101578.	0.7	11
61	Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. <i>Journal of Clinical Medicine</i> , 2020, 9, 3843.	1.0	10
62	Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. <i>International Journal of Drug Policy</i> , 2020, 86, 102964.	1.6	5
63	Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes. <i>Cancers</i> , 2020, 12, 3295.	1.7	8
64	Hepatic benefits of HCV cure. <i>Journal of Hepatology</i> , 2020, 73, 1548-1556.	1.8	64
65	Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. <i>Clinical Infectious Diseases</i> , 2021, 73, e2109-e2116.	2.9	10
66	Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-ALREAN cohort. <i>Journal of Medical Virology</i> , 2020, 92, 3545-3555.	2.5	4
67	Management of Hepatitis C-Infected Patients After Sustained Virological Response. <i>Clinical Liver Disease</i> , 2020, 16, 20-24.	1.0	2
68	Direct-acting antivirals restore systemic redox homeostasis in chronic HCV patients. <i>Free Radical Biology and Medicine</i> , 2020, 156, 200-206.	1.3	5
69	Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. <i>British Journal of Haematology</i> , 2020, 191, 775-783.	1.2	20
70	Pharmacist Interventions to Improve Specialty Medication Adherence: Study Protocol for a Randomized Controlled Trial. <i>Drugs - Real World Outcomes</i> , 2020, 7, 295-305.	0.7	8
71	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020, 73, 1170-1218.	1.8	671
72	Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 505-507.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
74	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. <i>BMC Gastroenterology</i> , 2020, 20, 251.	0.8	9
75	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
76	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757.	1.9	9
77	Reduction of Shear Wave Elastography but Not Shear Wave Dispersion After Successful Hepatitis C Treatment With Direct-Acting Antiviral Agents. <i>Journal of Ultrasound in Medicine</i> , 2020, 40, 1919-1926.	0.8	3
79	Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 257-259.	0.7	1
80	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	0.8	60
81	Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3057.	1.8	45
82	2-((4-Arylpiperazin-1-yl)methyl)benzotrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5972-5989.	2.9	10
83	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. <i>Journal of Hepatology</i> , 2020, 73, 794-799.	1.8	27
84	Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients—Relationship to smoking and alcohol. <i>JGH Open</i> , 2020, 4, 867-875.	0.7	3
85	Hepatitis C Virus Cure Is the Start of the End for Patients With Advanced Fibrosis/Cirrhosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2730-2731.	2.9	1
86	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	1.0	5
87	Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. <i>Cancers</i> , 2020, 12, 1351.	1.7	50
88	Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2020, 66, 245-252.	0.6	10
89	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	0.8	5
90	Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2020, 34, 245-255.	0.8	5
91	Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 301-314.	1.0	3

#	ARTICLE	IF	CITATIONS
92	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 347-360.	1.0	15
93	Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 63-70.	1.1	7
94	Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. <i>Journal of Viral Hepatitis</i> , 2020, 27, 996-1002.	1.0	7
95	A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma. <i>Cell</i> , 2020, 182, 317-328.e10.	13.5	53
96	Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication. <i>Journal of Infectious Diseases</i> , 2022, 226, 407-419.	1.9	7
97	Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria. <i>PLoS ONE</i> , 2020, 15, e0229239.	1.1	26
98	Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. <i>Journal of Hepatology</i> , 2020, 73, 277-284.	1.8	29
99	Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource. <i>Journal of Ethnopharmacology</i> , 2020, 255, 112735.	2.0	10
100	Epidemiological trend of hepatitis C-related liver events in Spain (2000–2015): A nationwide population-based study. <i>European Journal of Internal Medicine</i> , 2020, 75, 84-92.	1.0	7
101	The impact of SVR from direct-acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , 2020, 27, 781-793.	1.0	34
102	Hepatitis C: looking into the future. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 367-374.	1.4	4
103	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2554-2563.e3.	2.4	48
104	Personalized surveillance for hepatocellular carcinoma in cirrhosis—using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
105	Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: A randomized controlled trial protocol. <i>BMC Public Health</i> , 2020, 20, 1048.	1.2	5
106	Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0229143.	1.1	19
107	The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. <i>Journal of Clinical Medicine</i> , 2020, 9, 563.	1.0	18
108	Elimination of hepatitis C in Europe: can WHO targets be achieved?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 818-823.	2.8	26
109	Micro-elimination of hepatitis C virus. <i>Liver International</i> , 2020, 40, 67-71.	1.9	33

#	ARTICLE	IF	CITATIONS
110	IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. <i>Journal of Hepatology</i> , 2020, 73, 72-83.	1.8	14
111	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020, 40, 233-239.	1.8	4
112	Screening for Hepatitis C Virus Infection in Adolescents and Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 976.	3.8	46
113	Advances in resection and transplantation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 262-276.	1.8	107
114	Interferon-Free Hepatitis C Virus Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036855.	2.9	16
115	Long-term safety and efficacy results in hepatitis C virus genotype 1 infected patients receiving ombitasvir/paritaprevir/ritonavir±Dasabuvir±Sofosbuvir in the TOPAZ-1 and TOPAZ-2 trials. <i>Journal of Viral Hepatitis</i> , 2020, 27, 497-504.	1.0	10
116	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	1.0	21
117	Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 440.	1.2	1
118	A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. <i>Annals of Hepatology</i> , 2020, 19, 396-403.	0.6	7
119	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	1.8	38
120	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , 2020, 69, 2223-2231.	6.1	17
121	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	1.9	8
122	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Heparther cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101459.	0.7	4
123	Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?. <i>Clinical Infectious Diseases</i> , 2021, 72, 787-788.	2.9	0
124	Burden of Liver Cirrhosis in Portugal between 2010 and 2017. <i>GE Portuguese Journal of Gastroenterology</i> , 2021, 28, 153-161.	0.3	2
125	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , 2021, 74, 37-47.	1.8	21
126	Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1152-1158.	1.4	13
127	Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. <i>Journal of Gastroenterology</i> , 2021, 56, 90-100.	2.3	25

#	ARTICLE	IF	CITATIONS
128	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68
129	Liver Stiffness by Transient Elastography to Detect Portal Hypertension in Patients With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	3.6	40
130	“Dual aetiology fatty liver disease”: A recently proposed term associated with potential pitfalls. <i>Journal of Hepatology</i> , 2021, 74, 979-982.	1.8	14
131	Residual risk of liver disease after hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2021, 74, 952-963.	1.8	22
132	Carcinoma hepatocelular asociado con el uso de la terapia antiviral de acci3n directa para virus de hepatitis C: reporte de dos casos. <i>Revista De GastroenterologAa De MÃ©xico</i> , 2021, 86, 197-199.	0.4	4
133	High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 767-774.	1.4	6
134	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
135	Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 139-157.	0.8	5
136	Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. <i>Journal of Clinical Medicine</i> , 2021, 10, 353.	1.0	19
137	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. <i>Drugs</i> , 2021, 81, 419-443.	4.9	12
138	Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 94-96.	4.5	7
139	Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. <i>Global Health & Medicine</i> , 2021, 3, 321-334.	0.6	11
140	Human hepatitis viruses-associated cutaneous and systemic vasculitis. <i>World Journal of Gastroenterology</i> , 2021, 27, 19-36.	1.4	24
141	Incidence rates of hepatocellular carcinoma in relation to dynamic changes of liver fibrosis following viral clearance. <i>Journal of Public Health and Emergency</i> , 0, .	4.4	0
142	The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. <i>Canadian Liver Journal</i> , 2021, 4, 59-71.	0.3	2
143	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 739-754.	1.0	23
144	The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 2023.	1.3	4
145	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Î-Blocker Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1342-1344.	0.2	12

#	ARTICLE	IF	CITATIONS
146	Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study. <i>Pathogens and Disease</i> , 2021, 79, .	0.8	2
147	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 643-656.	1.4	8
148	Center-level Utilization of Hepatitis C Virus-“positive Donors for Orthotopic Heart Transplantation. <i>Transplantation</i> , 2021, 105, 2639-2645.	0.5	6
149	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. <i>Cancer Prevention Research</i> , 2021, 14, 581-592.	0.7	2
150	Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. <i>Journal of Clinical Medicine</i> , 2021, 10, 551.	1.0	17
151	Regression of portal hypertension: underlying mechanisms and therapeutic strategies. <i>Hepatology International</i> , 2021, 15, 36-50.	1.9	11
152	Epidemiological projections of viral-“induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. <i>Liver International</i> , 2021, 41, 915-927.	1.9	23
153	Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. <i>Viruses</i> , 2021, 13, 432.	1.5	3
154	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	1.9	20
155	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 119-126.	0.2	0
156	Programmed cell death-“ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2601-2609.	1.4	5
157	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
158	Diagn-“stico en un solo paso de la hepatitis C en 2019: una realidad en Espa-“a. <i>Enfermedades Infecciosas Y Microbiolog-“a Cl-“nica</i> , 2021, 39, 119-126.	0.3	15
159	Pretreatment non-“hypervascular hypointense nodules on Gd-“EOB-“DTPA-“enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1309-1316.	1.9	7
160	A population-based US study of hepatitis C diagnosis rate. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	4
161	Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases. <i>Revista De Gastroenterolog-“a De M-“xico (English Edition)</i> , 2021, 86, 197-199.	0.1	4
162	Serum Laminin -“2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775.	3.6	21
163	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	1.4	5

#	ARTICLE	IF	CITATIONS
164	Hepatitis C: clinical management and debated issues. <i>Minerva Medica</i> , 2021, 112, 228-237.	0.3	3
165	A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. <i>Hepatitis Monthly</i> , 2021, 21, .	0.1	3
166	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESISTâ€”HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	1.0	11
167	Epidemiology of hepatitis C virus infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101596.	0.7	53
168	Longâ€”term evolution of LIâ€”RADS observations in HCVâ€”related cirrhosis treated with directâ€”acting antivirals. <i>Liver International</i> , 2021, 41, 2179-2188.	1.9	3
169	Safety of Patients with Hepatitisâ€”C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. <i>Advances in Therapy</i> , 2021, 38, 3409-3426.	1.3	7
170	The role of liver and spleen elastography in advanced chronic liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 151-163.	0.3	4
171	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 413.	1.3	12
172	Modifications of liver stiffness and CXCL4, TGF-Î²1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. <i>Scientific Reports</i> , 2021, 11, 9824.	1.6	2
173	Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with directâ€”acting antivirals. <i>GastroHep</i> , 2021, 3, 185-195.	0.3	3
174	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	1.8	42
175	Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. <i>Aids</i> , 2021, 35, 2119-2127.	1.0	4
176	Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. <i>Kidney360</i> , 2021, 2, 1316-1325.	0.9	0
177	A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. <i>Gastroenterology Research</i> , 2021, 14, 139-156.	0.4	8
178	Is elimination of HCV realistic by 2030: France. <i>Liver International</i> , 2021, 41, 45-49.	1.9	9
179	High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55â€”85. <i>Pathogens</i> , 2021, 10, 695.	1.2	5
180	Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. <i>Journal of Hepatology</i> , 2021, 75, 1049-1057.	1.8	36
181	Directâ€”Acting Antiviral Therapy and Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 414-417.	1.0	4

#	ARTICLE	IF	CITATIONS
182	Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. <i>Liver Cancer</i> , 2021, 10, 309-319.	4.2	16
183	Patients'™ preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection. <i>Revista Española De Sanidad Penitenciaria</i> , 2021, 23, 67-75.	0.5	1
184	Current impact of viral hepatitis on liver cancer development: The challenge remains. <i>World Journal of Gastroenterology</i> , 2021, 27, 3556-3567.	1.4	11
185	Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. <i>Scientific Reports</i> , 2021, 11, 13543.	1.6	15
186	Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. <i>Scientific Reports</i> , 2021, 11, 11681.	1.6	13
187	HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. <i>Cancers</i> , 2021, 13, 3025.	1.7	6
188	Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched. <i>World Journal of Gastroenterology</i> , 2021, 27, 2771-2783.	1.4	5
189	Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 565-574.	1.8	1
190	Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. <i>JHEP Reports</i> , 2021, 3, 100289.	2.6	12
191	Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. <i>Metabolism Open</i> , 2021, 10, 100090.	1.4	16
192	Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 856-864.	0.5	6
193	Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1246-1255.	1.0	1
194	Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. <i>Kidney International Reports</i> , 2021, 6, 1788-1798.	0.4	2
195	The immunological and metabolic landscape in primary and metastatic liver cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 541-557.	12.8	212
196	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <i>Hepatology Research</i> , 2021, 51, 725-749.	1.8	90
197	Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 761.	0.8	5
198	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. <i>Cancers</i> , 2021, 13, 3694.	1.7	16
199	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1293-1303.	1.0	1

#	ARTICLE	IF	CITATIONS
200	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 593-619.	2.3	158
201	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021, 2, 836-850.e10.	2.2	31
202	Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfecting participants. <i>HIV Medicine</i> , 2021, 22, 791-804.	1.0	1
203	Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents. <i>Journal of Occupational Medicine and Toxicology</i> , 2021, 16, 34.	0.9	2
204	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	2.6	6
205	Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2390-2398.	0.2	19
206	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. <i>Diagnostics</i> , 2021, 11, 1501.	1.3	2
207	Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2021, 21, .	0.1	0
208	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , 2021, 22, 924-935.	1.0	2
209	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4387.	1.7	15
210	Hepatitis C virus infection and anaesthesia practice: A narrative review. <i>Anaesthesia and Intensive Care</i> , 2021, 49, 349-356.	0.2	0
211	Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	1
212	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	1.8	676
213	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	1.0	10
215	Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?. <i>European Journal of Internal Medicine</i> , 2021, 94, 6-14.	1.0	5
216	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <i>Journal of Clinical Virology</i> , 2021, 144, 104987.	1.6	2
217	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. <i>Journal of Hepatology</i> , 2022, 76, 302-310.	1.8	48
218	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 38-49.	1.9	5

#	ARTICLE	IF	CITATIONS
219	p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 95-112.	2.3	5
220	International Multicenter Validation of GES Score for HCC Risk Stratification in Chronic Hepatitis C Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
221	Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
222	Genetic variation in IL-10 influences the progression of hepatitis B infection. <i>International Journal of Infectious Diseases</i> , 2020, 96, 260-265.	1.5	14
223	Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018). <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 279-287.	0.8	1
224	Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. <i>Cancer Science</i> , 2020, 111, 2747-2759.	1.7	19
225	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
226	Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. <i>Liver International</i> , 2021, 41, 276-287.	1.9	15
227	Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. <i>PLoS ONE</i> , 2020, 15, e0243725.	1.1	7
228	Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus. <i>Internal Medicine</i> , 2020, 59, 2653-2660.	0.3	13
229	Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	14
230	Therapy Implications of Hepatitis C Virus Genetic Diversity. <i>Viruses</i> , 2021, 13, 41.	1.5	32
231	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947.	1.4	11
232	Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. <i>World Journal of Gastroenterology</i> , 2020, 26, 6770-6781.	1.4	27
233	A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. <i>Gut and Liver</i> , 2020, 14, 808-816.	1.4	9
234	Serum Î±fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2021, , .	1.0	4
235	Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct-acting antiviral-induced sustained virologic response. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	3
236	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10

#	ARTICLE	IF	CITATIONS
237	Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. <i>Aids</i> , 2021, 35, 2211-2213.	1.0	0
238	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 112, 64-70.	0.1	4
239	Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. <i>Future Virology</i> , 2019, 14, 715-727.	0.9	0
241	Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2020, 75, 308-310.	0.2	0
242	The role of dentists in controlling hepatocellular carcinoma in Japan (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 113.	0.8	2
243	Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 538-544.	0.1	0
244	Global Trends and Regional Differences in Hepatitis C Virus Infection Prevalence and Implications for Prevention – Worldwide, 1990–2017. <i>China CDC Weekly</i> , 2020, 2, 564-569.	1.0	4
245	Simple Stratification of Hepatocellular Carcinoma Surveillance after Direct-acting Antiviral Therapy for Chronic Hepatitis C. <i>The Showa University Journal of Medical Sciences</i> , 2020, 32, 125-133.	0.1	0
246	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	2.6	15
248	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. <i>Journal of Infectious Diseases</i> , 2020, 222, S741-S744.	1.9	1
249	Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 303-306.	0.2	3
250	FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 661-664.	0.7	0
251	Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 3091.	1.8	13
252	Consensus on the secondary prevention of primary liver cancer. <i>Hepatology International</i> , 2021, 15, 1289-1300.	1.9	8
253	Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. <i>Hepatology</i> , 2022, 75, 1247-1256.	3.6	11
254	Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. <i>Pathogens</i> , 2021, 10, 1488.	1.2	5
255	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
256	Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab525.	0.4	5

#	ARTICLE	IF	CITATIONS
257	Development and multicenter validation of FIB-4: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2022, 52, 165-175.	1.8	7
258	Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 55, 422.	1.9	9
259	Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).. <i>Lancet Regional Health - Europe, The</i> , 2022, 13, 100281.	3.0	10
260	FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 661-664.	0.7	1
261	Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 799382.	1.5	1
262	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
263	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. <i>Journal of Gastroenterology</i> , 2022, 57, 90-98.	2.3	6
264	Hepatectomy outcomes in patients with hepatitis C virus-related hepatocellular carcinoma with or without cirrhosis. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 1.	0.4	5
265	Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study. <i>Hepatology International</i> , 2022, 16, 159-170.	1.9	5
266	Hepatitis C virus: A critical approach to who really needs treatment. <i>World Journal of Hepatology</i> , 2022, 14, 1-44.	0.8	3
267	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. <i>JAMA Network Open</i> , 2022, 5, e2143050.	2.8	1
268	Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. <i>World Journal of Hepatology</i> , 2022, 14, 62-79.	0.8	3
269	Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study. <i>Liver International</i> , 2022, 42, 561-574.	1.9	8
270	Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. <i>Scientific Reports</i> , 2022, 12, 1517.	1.6	10
271	Resource Management through Artificial Intelligence in Screening Programs—Key for the Successful Elimination of Hepatitis C. <i>Diagnostics</i> , 2022, 12, 346.	1.3	5
272	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 824879.	1.6	0
273	Viral hepatitis: Innovations and expectations. <i>World Journal of Gastroenterology</i> , 2022, 28, 517-531.	1.4	13
274	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	1.8	19

#	ARTICLE	IF	CITATIONS
275	Associations of DDX60L With the Clinical Features and Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 761021.	1.3	0
276	Present and future management of viral hepatitis. <i>World Journal of Gastroenterology</i> , 2021, 27, 8081-8102.	1.4	2
277	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59
278	Changes in proportionate cardiovascular mortality in patients with chronic infectious and inflammatory conditions in the United States, 1999â€“2018. <i>Scientific Reports</i> , 2021, 11, 23985.	1.6	7
279	Similar 5â€“year HCC occurrence in Tenofovirâ€“and Entecavirâ€“treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 616-629.	1.9	15
280	Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts. <i>Advances in Cancer Research</i> , 2022, , .	1.9	0
281	Chronic Viral Hepatitis C: Before and after Direct Acting Antivirals (DAA) in Morocco. <i>Open Journal of Gastroenterology</i> , 2022, 12, 55-63.	0.1	0
282	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 693-697.	0.8	4
283	Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?. <i>Biomedicines</i> , 2022, 10, 534.	1.4	4
284	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. <i>PLoS ONE</i> , 2022, 17, e0264075.	1.1	2
285	Characteristics of Persons Treated for Hepatitis C Using National Pharmacy Claims Data, United States, 2014â€“2020. <i>Clinical Infectious Diseases</i> , 2022, 75, 1078-1080.	2.9	16
286	The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. <i>Clinical and Experimental Medicine</i> , 2023, 23, 255-272.	1.9	11
287	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	2.6	3
289	Impact of HCV Infection on Hepatocyte Polarity and Plasticity. <i>Pathogens</i> , 2022, 11, 337.	1.2	1
290	Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101848.	0.7	8
291	Racial disparity in age and genotype defines urban hepatitis C patient profiles in the recent direct-acting antiviral era. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2021, 12, 190-197.	0.0	0
292	Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. <i>Livers</i> , 2021, 1, 313-321.	0.8	2
293	Big Data Information under Proportional Hazard Mathematical Model in Analysis of Hepatitis B Virus Infection Data of Patients with Interventional Liver Cancer through Antiviral Therapy of Entecavir. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-8.	1.1	1

#	ARTICLE	IF	CITATIONS
294	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1919-1938.	0.8	15
295	High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program – A Prospective Nationwide, Population-Based Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1732-1739.	2.9	8
296	OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT. <i>Ulyanovsk Medico-biological Journal</i> , 2022, , 39-48.	0.0	0
297	Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1166-1182.	1.9	6
298	The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C. , 2022, 1, 508-515.		0
299	HARVONI VERSUS 3D REGIMENS OUTCOMES AMONG HCV INFECTED PATIENTS VISITED KURDISTAN CENTRE FOR GASTROENTEROLOGY AND HEPATOLOGY (KCGH). <i>Journal of Sulaimani Medical College</i> , 2022, 12, 1-9.	0.0	0
300	PECULIARITIES OF TREATMENT AND PREVENTION OF INFECTION CAUSED BY HEPATITIS C VIRUS. Review. <i>Medical Science of Ukraine (MSU)</i> , 2022, 18, 64-72.	0.0	0
301	Revolution in the diagnosis and management of hepatitis C virus infection in current era. <i>World Journal of Hepatology</i> , 2022, 14, 647-669.	0.8	2
302	Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. <i>JGH Open</i> , 0, , .	0.7	1
303	Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection. <i>PLoS ONE</i> , 2022, 17, e0268478.	1.1	4
304	O vÃrus da Hepatite C e a Hepatite C. , 2021, , 53-76.		0
306	Chronic hepatitis C: Diagnosis and treatment made easy. <i>European Journal of General Practice</i> , 2022, 28, 102-108.	0.9	10
307	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. <i>Journal of Hepatology</i> , 2022, 76, 1362-1378.	1.8	78
308	Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1723-1738.e5.	2.4	12
309	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis. <i>Hepatology Research</i> , 2022, 52, 665-676.	1.8	4
310	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
311	Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182210958.	0.5	2
312	A Prospective Study for Validation of General Evaluation Score for Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis C Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
313	Research on Lightweight Disaster Classification Based on High-Resolution Remote Sensing Images. <i>Remote Sensing</i> , 2022, 14, 2577.	1.8	6
314	Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. <i>Hepatology Communications</i> , 2022, 6, 2496-2512.	2.0	4
315	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 2251-2281.	1.4	23
316	Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?. <i>Vaccines</i> , 2022, 10, 891.	2.1	1
317	International multicenter validation of <scp>GES</scp> score for <scp>HCC</scp> risk stratification in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2022, 29, 807-816.	1.0	4
318	“Shaping the new freedom”: A reflexive thematic analysis on patients’ post cure needs after years of living with hepatitis C. <i>Swiss Medical Weekly</i> , 2022, 152, w30177.	0.8	4
319	Fibrosis regression following hepatitis C antiviral therapy. <i>World Journal of Hepatology</i> , 2022, 14, 1120-1130.	0.8	5
320	Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1654-1665.	1.4	3
321	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. <i>JGH Open</i> , 2022, 6, 462-469.	0.7	2
322	Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory. <i>Liver International</i> , 2022, 42, 2299-2316.	1.9	13
323	Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, , .	1.5	1
324	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
325	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2022, 29, 919-929.	1.0	5
326	Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 4049.	1.0	6
327	Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
329	<i>Vital Signs:</i> Hepatitis C Treatment Among Insured Adults – United States, 2019–2020. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 1011-1017.	9.0	36
330	Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102697.	0.3	3
331	Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents. <i>JGH Open</i> , 2022, 6, 685-691.	0.7	2

#	ARTICLE	IF	CITATIONS
332	Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. <i>World Journal of Gastroenterology</i> , 2022, 28, 4182-4200.	1.4	1
333	Infection chronique par le virus de l'hépatite C. <i>Medecine/Sciences</i> , 2022, 38, 640-642.	0.0	0
334	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. <i>Global Health & Medicine</i> , 2022, 4, 216-224.	0.6	1
335	The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	9
336	Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders. <i>Haemophilia</i> , 2023, 29, 106-114.	1.0	3
337	The 11th Canadian Symposium on Hepatitis C Virus: "Getting back on track towards hepatitis C elimination". <i>Canadian Liver Journal</i> , 0, , .	0.3	0
338	Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts. <i>Journal of Viral Hepatitis</i> , 0, , .	1.0	1
339	Individual and Community-Level Characteristics and Adherence to Specialty Medications. <i>Journal of Pharmacy Practice</i> , 2024, 37, 279-286.	0.5	0
340	Management of ACLD After HBV-Suppression and HCV-Cure. , 2022, , 239-252.		0
341	Epidemiological Aspects of Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 3-9.	0.0	0
342	Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts. <i>PLoS ONE</i> , 2022, 17, e0276925.	1.1	1
343	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 583-705.	4.5	102
345	Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR. <i>Viruses</i> , 2022, 14, 2412.	1.5	3
346	Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. <i>Journal of Personalized Medicine</i> , 2022, 12, 1794.	1.1	0
347	Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System. <i>International Journal of Clinical Pharmacy</i> , 0, , .	1.0	1
348	Multiscale Element-Doped Nanowire Array-Coupled Machine Learning Reveals Metabolic Fingerprints of Nonreversible Liver Diseases. <i>Analytical Chemistry</i> , 2022, 94, 16204-16212.	3.2	6
350	A micropeptide JunBP regulated by TGF- β 2 promotes hepatocellular carcinoma metastasis. <i>Oncogene</i> , 2023, 42, 113-123.	2.6	4
351	Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature. <i>Journal of Medicine and Life</i> , 2022, 15, 1257-1266.	0.4	0

#	ARTICLE	IF	CITATIONS
352	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
353	Update on the role of elastography in liver disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211406.	1.4	12
354	Trajectories of De Ritis ratio with risk of hepatocellular carcinoma and liver-related mortality following direct-acting antivirals for HCV: A retrospective longitudinal study up to 10 years. Carcinogenesis, 0, , .	1.3	0
355	Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. Journal of Viral Hepatitis, 2023, 30, 148-159.	1.0	2
356	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer, 2023, 23, 1-120.	0.3	24
358	Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the <scp>ANRS CO22 HEPATHER</scp> cohort. Journal of Viral Hepatitis, 2023, 30, 232-241.	1.0	2
359	Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Internal Medicine, 2023, 183, 97.	2.6	23
360	Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1279-1298.	1.8	2
361	Virtual Screening of Telaprevir and Danoprevir Derivatives for Hepatitis C Virus NS3/4A Protease Inhibitors. Letters in Drug Design and Discovery, 2024, 21, 809-822.	0.4	0
363	HIV-HCV Incidence in Low-Wage Agricultural Migrant Workers Living in Ghettos in Apulia Region, Italy: A Multicenter Cross Sectional Study. Viruses, 2023, 15, 249.	1.5	1
364	Erkrankungen von Leber und Pankreas. , 2022, , 475-542.		0
365	Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990â€”2019: A DALY-based analysis of the Global Burden of Disease 2019 study. Clinical and Molecular Hepatology, 2023, 29, 433-452.	4.5	14
366	Risk factors for liverâ€related and nonâ€liverâ€related mortality following a sustained virological response after directâ€acting antiviral treatment for hepatitis C virus infection in a realâ€world cohort. Journal of Viral Hepatitis, 2023, 30, 374-385.	1.0	1
367	Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines, 2023, 11, 166.	1.4	6
368	Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. Journal of Gastroenterology, 0, , .	2.3	1
369	Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 2023, 43, 917-927.	1.9	8
370	Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus. , 2023, 1, 5-10.		0
371	Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges. , 2023, , 231-289.		0

#	ARTICLE	IF	CITATIONS
372	Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C. <i>Gastroenterology & Hepatology</i> , 2023, 46, 754-763.	0.2	2
373	Polymorphisms within DIO2 and GADD45A genes increase the risk of liver disease progression in chronic hepatitis b carriers. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
374	The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. <i>Medical Clinics of North America</i> , 2023, 107, 397-421.	1.1	2
375	Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes. <i>JAMA Internal Medicine</i> , 2023, 183, 624.	2.6	1
376	Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study. <i>Arab Journal of Gastroenterology</i> , 2023, , .	0.4	0
377	Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. <i>Digestive and Liver Disease</i> , 2023, 55, 907-917.	0.4	5
378	A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019. <i>Eurosurveillance</i> , 2023, 28, .	3.9	1
379	The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population. <i>Hepatology International</i> , 2023, 17, 562-572.	1.9	1
381	Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 597-605.	0.5	0
382	Prognostic significance of the preoperative alkaline phosphatase to albumin ratio in patients with hepatocellular carcinoma after hepatic resection. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
383	Prediction of hepatic decompensation and hepatocellular carcinoma after direct-acting antiviral therapy in patients with hepatitis C-related liver cirrhosis: a cohort study. <i>Egyptian Liver Journal</i> , 2023, 13, .	0.3	0
384	Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens. <i>Viruses</i> , 2023, 15, 677.	1.5	1
385	Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS). <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
386	Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90 α . <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1637-1648.	2.8	4
387	Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 413-428.	1.8	10
388	Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients. <i>Journal of Viral Hepatitis</i> , 2023, 30, 567-577.	1.0	1
389	Statin Utilization Among Individuals Infected With Hepatitis C Virus: A Retrospective Cohort Study. <i>Cureus</i> , 2023, , .	0.2	0
390	Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals. <i>Journal of Clinical Medicine</i> , 2023, 12, 2195.	1.0	2

#	ARTICLE	IF	CITATIONS
391	In Vivo and in Vitro Biocompatibility Studies of Pt Based Nanoparticles: a New Agent for Chemoradiation Therapy. Journal of Cluster Science, 2023, 34, 2653-2663.	1.7	1
393	Patient-Tailored Interventions to Improve Specialty Medication Adherence: Results from a Prospective Randomized Controlled Trial. American Journal of Medicine, 2023, 136, 694-701.e1.	0.6	1
394	Staging liver fibrosis with shear wave elastography. , 2024, , 95-124.		0
395	Mortality in HCV-cured versus HCV-uninfected people with HIV: a matched analysis in the ANRS CO4 FHDH cohort. Aids, 0, Publish Ahead of Print, .	1.0	0
424	Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397, 1421-1431.	1.4	1
443	Vasculitides and Hepatitis C Infection. , 2024, , 317-335.		0